Sign In
Buy FDMT
$9.53
+0.260 (+2.80%)
At Close: Jun 03, 2026
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT
07:40pm, Monday, 26'th Aug 2024
NEW YORK , Aug. 26, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of 4D Molecular Therapeutics, Inc. ("4D" or the "Company") (NASDAQ: FDMT). Such investors are adv
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT
09:40am, Saturday, 24'th Aug 2024
NEW YORK, NY / ACCESSWIRE / August 24, 2024 / Pomerantz LLP is investigating claims on behalf of investors of 4D Molecular Therapeutics, Inc. ("4D" or the "Company") (NASDAQ: FDMT). Such investors are
4D Molecular Therapeutics (FDMT) Loses -21.87% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
10:35am, Friday, 23'rd Aug 2024
4D Molecular Therapeutics (FDMT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising ea
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT
12:00am, Thursday, 22'nd Aug 2024
NEW YORK, NY / ACCESSWIRE / August 22, 2024 / Pomerantz LLP is investigating claims on behalf of investors of 4D Molecular Therapeutics, Inc. ("4D" or the "Company") (NASDAQ:FDMT). Such investors are
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT
10:00am, Wednesday, 21'st Aug 2024
NEW YORK, NY / ACCESSWIRE / August 21, 2024 / Pomerantz LLP is investigating claims on behalf of investors of 4D Molecular Therapeutics, Inc. ("4D" or the "Company") (NASDAQ:FDMT). Such investors are
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT
12:00pm, Monday, 19'th Aug 2024
NEW YORK, NY / ACCESSWIRE / August 19, 2024 / Pomerantz LLP is investigating claims on behalf of investors of 4D Molecular Therapeutics, Inc. ("4D" or the "Company") (NASDAQ:FDMT). Such investors are
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT
10:00pm, Saturday, 17'th Aug 2024
NEW YORK , Aug. 17, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of 4D Molecular Therapeutics, Inc. ("4D" or the "Company") (NASDAQ: FDMT). Such investors are ad
4DMT to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
08:00am, Monday, 12'th Aug 2024
EMERYVILLE, Calif., Aug. 12, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full p
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT
10:00am, Sunday, 11'th Aug 2024
NEW YORK, NY / ACCESSWIRE / August 11, 2024 / Pomerantz LLP is investigating claims on behalf of investors of 4D Molecular Therapeutics, Inc. ("4D" or the "Company") (NASDAQ:FDMT). Such investors are
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT
11:45am, Friday, 09'th Aug 2024
NEW YORK , Aug. 9, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of 4D Molecular Therapeutics, Inc. ("4D" or the "Company") (NASDAQ: FDMT). Such investors are advis
4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Lags Revenue Estimates
06:56pm, Thursday, 08'th Aug 2024
4D Molecular Therapeutics, Inc. (FDMT) came out with a quarterly loss of $0.63 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to loss of $0.77 per share a year ago.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT
12:45pm, Wednesday, 07'th Aug 2024
NEW YORK, NY / ACCESSWIRE / August 7, 2024 / Pomerantz LLP is investigating claims on behalf of investors of 4D Molecular Therapeutics, Inc. ("4D" or the "Company") (NASDAQ:FDMT). Such investors are a
EMERYVILLE, Calif., Aug. 05, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full p
NEW YORK, NY / ACCESSWIRE / August 2, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of 4D Molecular Therapeutics, Inc. ("4D Molecular" or "the Com
NEW YORK, NY / ACCESSWIRE / August 1, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of 4D Molecular Therapeutics, Inc. ("4D Molecular" or "the Com
